Nymox Pharmaceutical Corp SEC filings NYMXF
Nymox Pharmaceutical Corp has 408 filings in SEC EDGAR's recent list, going back to Aug 8, 1996. Its latest annual report, Form 20-F, was filed on Sep 14, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Aug 31, 2026. The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 20-F/A | Amended annual report (foreign issuer) | Sep 29, 2026 | Dec 31, 2025 |
| 20-F/A | Amended annual report (foreign issuer) | Sep 16, 2026 | Dec 31, 2025 |
| 20-F | Annual report (foreign issuer) | Sep 14, 2026 | Dec 31, 2025 |
| 20-F | Annual report (foreign issuer) | Jun 3, 2025 | Dec 31, 2024 |
| 20-F | Annual report (foreign issuer) | Aug 29, 2024 | Dec 31, 2023 |
| 20-F | Annual report (foreign issuer) | May 2, 2023 | Dec 31, 2022 |
| 20-F | Annual report (foreign issuer) | Mar 30, 2022 | Dec 31, 2021 |
| 20-F/A | Amended annual report (foreign issuer) | Jun 11, 2021 | Dec 31, 2020 |
| 20-F | Annual report (foreign issuer) | Mar 29, 2021 | Dec 31, 2020 |
| 20-F | Annual report (foreign issuer) | Mar 30, 2020 | Dec 31, 2019 |
| 20-F | Annual report (foreign issuer) | Mar 29, 2019 | Dec 31, 2018 |
| 20-F/A | Amended annual report (foreign issuer) | May 11, 2018 | Dec 31, 2017 |
| 20-F | Annual report (foreign issuer) | Mar 30, 2018 | Dec 31, 2017 |
| 20-F | Annual report (foreign issuer) | Mar 31, 2017 | Dec 31, 2016 |
| 20-F | Annual report (foreign issuer) | Mar 31, 2016 | Dec 31, 2015 |
| 20-F | Annual report (foreign issuer) | Mar 31, 2015 | Dec 31, 2014 |
| 20-F | Annual report (foreign issuer) | Mar 14, 2014 | Dec 31, 2013 |
| 20-F | Annual report (foreign issuer) | Mar 15, 2013 | Dec 31, 2012 |
| 20-F | Annual report (foreign issuer) | Mar 15, 2012 | Dec 31, 2011 |
| 20-F/A | Amended annual report (foreign issuer) | Jun 3, 2011 | Dec 31, 2010 |
| 20-F | Annual report (foreign issuer) | Mar 15, 2011 | Dec 31, 2010 |
| 20-F | Annual report (foreign issuer) | Mar 11, 2010 | Dec 31, 2009 |
| 20-F | Annual report (foreign issuer) | Mar 13, 2009 | Dec 31, 2008 |
| 20-F | Annual report (foreign issuer) | Apr 28, 2008 | Dec 31, 2007 |
| 20-F | Annual report (foreign issuer) | Jun 26, 2007 | Dec 31, 2006 |
| 20-F | Annual report (foreign issuer) | Jun 30, 2006 | Dec 31, 2005 |
| 20-F/A | Amended annual report (foreign issuer) | Oct 24, 2005 | Dec 31, 2004 |
| 20-F | Annual report (foreign issuer) | Jun 30, 2005 | Dec 31, 2004 |
| 20-F | Annual report (foreign issuer) | Jun 30, 2004 | Dec 31, 2003 |
| 20-F/A | Amended annual report (foreign issuer) | Jun 19, 2003 | Dec 31, 2002 |
| 20-F | Annual report (foreign issuer) | May 27, 2003 | Dec 31, 2002 |
| 20-F/A | Amended annual report (foreign issuer) | Jul 25, 2002 | Dec 31, 2001 |
| 20-F | Annual report (foreign issuer) | Jun 27, 2002 | Dec 31, 2001 |
| 20-F | Annual report (foreign issuer) | May 8, 2001 | Dec 31, 2000 |
| 20-F | Annual report (foreign issuer) | May 15, 2000 | Dec 31, 1999 |
| 20-F | Annual report (foreign issuer) | May 14, 1999 | Dec 31, 1998 |
| 20-F | Annual report (foreign issuer) | May 8, 1998 | Dec 31, 1997 |
Showing 37 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- NYMXF (OTC)
- Fiscal year ends
- December 31
- Headquarters
- Quebec Canada, Quebec, Canada
- SEC filer status
- Accelerated filer
- SEC CIK
- 1018735
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
Source: SEC EDGAR filings. This is company-reported data, not investment advice.